Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695501 versus Humira in moderate to severe chronic plaque psoriasis
2016-000613-79Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing BI 695501 with Humira (2 arms). Primary endpoint: Proportion of patients with PASI 75 at Week 16. Started Jun 2016; status: completed.
02
Drugs
adalimumab-adbmadalimumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2016-000613-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000613-79.